Chapter 12: Lupus nephritis  by unknown
Chapter 12: Lupus nephritis
Kidney International Supplements (2012) 2, 221–232; doi:10.1038/kisup.2012.25
INTRODUCTION
This chapter makes treatment recommendations for LN
in adults and children. The cost implications for global
application of this guideline are addressed in Chapter 2.
BACKGROUND
Kidney involvement in systemic lupus, known as LN, is most
often due to glomerular immune complex accumulation,
which leads to glomerular inflammation and, if unchecked,
also involves the renal interstitium. The kidney may also
sustain damage by other mechanisms, such as thrombotic
microangiopathy. Lupus patients with LN have worse
outcomes than those with no kidney involvement.586–588
This poor prognosis is explained only in part by the risk of
CKD and ESRD, suggesting that LN is a manifestation of a
more severe form of systemic lupus.
The reported incidence of clinically important kidney
disease in systemic lupus is about 38%. Of those who develop
clinical LN, 40–60% have overt kidney disease at the time
lupus is diagnosed.589–591 The incidence of kidney involve-
ment differs with ethnicity. Caucasians (European, European
Americans; 12–33%) are less likely to have LN than black
(African American, Afro-Caribbean; 40–69%), Hispanic
(36–61%), or Asian (Indian, Chinese; 47–53%) patients.
Based on the United States Renal Data Service database,
between 1996 and 2004 the incidence of ESRD attributed to
LN in adults was 4.5 cases per million in the general
population,592 but was greater in blacks (17–20/million) and
Hispanics (6/million) than Caucasians (2.5/million). Simi-
larly, a retrospective cohort from the UK found that 19% of
Caucasians and 62% of blacks with LN progressed to
ESRD.593 In a Saudi Arabian population, 12% of patients
with LN developed ESRD.589,594 The prevalence of CKD in
patients with systemic lupus is difficult to estimate, but
because current therapies induce complete remission in only
about 50% of those with LN, CKD is likely to be common.
The presence of LN should be considered in any lupus patient
with impaired kidney function, proteinuria, hypertension, or an
active urine sediment. An active sediment includes hematuria,
especially acanthocytes suggestive of glomerular bleeding, leuko-
cyturia in the absence of infection, and red and white blood cell
casts. LN must be confirmed by kidney biopsy. The histologic
findings provide the basis for treatment recommendations for LN.
12.1: Class I LN (minimal-mesangial LN)
12.1.1: We suggest that patients with class I LN be
treated as dictated by the extrarenal clinical
manifestations of lupus. (2D)
BACKGROUND
In class I LN, glomeruli are normal by light microscopy. Class
I LN is defined by the presence of immune deposits restricted
to the mesangium, and seen only by immunofluorescence or
electron microscopy.
RATIONALE
K Class I LN has no clinical kidney manifestations.
K Class I LN is not associated with long-term impairment
of kidney function.
Kidney tissue obtained for research purposes in patients
with systemic lupus but without clinical signs of kidney
disease showed LN was present in about 90% of
patients,595,596 far more than the 40% or so who manifest
clinical kidney disease. In some patients with clinically silent
class I LN, there is transformation to more aggressive and
clinically relevant forms of LN.597 However, at present, there
are no data to suggest that every patient with lupus requires a
kidney biopsy, or that treatment of class I LN is clinically
necessary.
12.2: Class II LN (mesangial-proliferative LN)
12.2.1: Treat patients with class II LN and proteinuria
o1 g/d as dictated by the extrarenal clinical
manifestations of lupus. (2D)
12.2.2: We suggest that class II LN with proteinuria
43 g/d be treated with corticosteroids or CNIs
as described for MCD (see Chapter 5). (2D)
BACKGROUND
The kidney biopsy of class II LN shows mesangial
hypercellularity and matrix expansion on light microscopy,
and mesangial immune deposits by immunofluorescence and
electron microscopy. Clinically, proteinuria and/or hematuria
may be seen in class II LN, but usually not nephrotic
syndrome, or kidney impairment. If nephrotic-range protei-
nuria is found with class II LN, this may be due to a
concomitant podocytopathy.
RATIONALE
K There are no evidence-based data on the treatment of
class II LN.
K Podocytopathies, characterized histologically by diffuse
foot process effacement in the absence of glomerular
capillary wall immune complex deposition or endo-
capillary proliferation, have been observed in patients
with class II LN.
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Podocyte injury in class II LN does not appear related to the
extent of mesangial immune complex deposition.598 While
there have been no prospective studies of the treatment of
nephrotic-range proteinuria in class II LN, it is reasonable to
treat such patients as for MCD/FSGS in case of nephrotic
syndrome, or if proteinuria cannot be controlled using RAS
blockade.
12.3: Class III LN (focal LN) and class IV LN (diffuse LN)—
initial therapy
12.3.1: We recommend initial therapy with cortico-
steroids (1A), combined with either cyclo-
phosphamide (1B) or MMF (1B).
12.3.2: We suggest that, if patients have worsening LN
(rising SCr, worsening proteinuria) during the
first 3 months of treatment, a change be made
to an alternative recommended initial therapy,
or a repeat kidney biopsy be performed to
guide further treatment. (2D)
BACKGROUND
Class III and IV LN are differentiated by the percentage of
affected glomeruli (class III, o50%; class IV, Z50%).
Glomerular lesions are classified as active (A) or chronic
(C). The active lesions of class III and IV are endocapillary
and (usually) mesangial hypercellularity, crescents, necrosis,
wire loops, and hyaline thrombi. Chronic lesions include
segmental and global glomerulosclerosis. Immunofluores-
cence and electron microscopy show significant subendothe-
lial and mesangial immune deposits. If there are extensive
subepithelial immune deposits, there is coincidental class V
LN (see Rationale).
Almost all patients will have microscopic hematuria and
proteinuria; nephrotic syndrome and kidney impairment are
common. However, if the histologic lesions are mainly chronic
(see Rationale) there may be less overt clinical activity, other
than progressive kidney failure. Therapy should be adjusted
according to the extent of activity or chronicity.
There is no standard definition of treatment response for
class III and IV LN, which makes direct comparison of
clinical trials difficult. Nonetheless, the overall goals of
treatment are similar between trials, and definitions of
response based on published trials are provided as a guide to
the success of therapy (Table 27).
RATIONALE
K Proliferative LN (class III or IV) is an aggressive disease.
K Before 1970, kidney survival and overall patient survival
in diffuse proliferative LN were very poor, in the range of
20–25%.
K Patient and kidney survival in class III and IV LN have
dramatically improved through the use of intensive
immunosuppression.
K The International Society of Nephrology/Renal Pathology
Society classification of LN assigns activity (A) or
chronicity (C) in class III and IV LN. Our treatment
recommendations are for active or active plus chronic
lesions. Thorough review with the nephropathologist is
required to ensure accurate classification prior to starting
therapy.
K Therapy for class III and IV LN has initial and maintenance
phases. The objective is to rapidly decrease kidney inflam-
mation by initial intensive treatment, and then consolidate
treatment over a longer time. The initial phase is often
called induction, which implies remission is achieved at
its completion. This, however, is often not the case, and
remissions continue to occur well into the maintenance
phase. The term ‘‘initial’’ treatment is therefore preferred.
K The benefit of the addition of cyclophosphamide to
corticosteroids for initial treatment was shown in
controlled trials demonstrating that, during long term
follow-up, this combination decreased the frequency of
kidney relapse, CKD, and ESRD compared to cortico-
steroids alone.
K The evolution of initial therapy in proliferative LN has
been to reduce toxicity while maintaining efficacy. This
has resulted in several modifications of cyclophospha-
mide dosing, and the introduction of MMF as an
alternative to cyclophosphamide.
K The efficacy of newer initial treatment regimens should
be assessed not only by initial responses, but also by long-
term effects on kidney relapse, and development of CKD.
Widely used treatment regimens are shown in Table 28.
Increases in disease activity in systemic lupus in general,
and in LN in particular, may be described as ‘‘flares’’ or
‘‘relapses’’. In this guideline, we use the term ‘‘relapse’’.
Corticosteroids
All regimens use similar corticosteroid dosing: an initial dose
of oral prednisone up to 1mg/kg, tapering according to
clinical response over 6–12 months. Additional i.v. methyl-
prednisolone is widely used at the beginning of treatment for
more severe disease. However, the dosing and duration of
corticosteroids has never been subject to evaluation by RCTs.
Cyclophosphamide
i.v. cyclophosphamide (0.5–1 g/m2) given monthly for 6
months (Regimen A, sometimes called the ‘‘NIH regimen’’)
was the first immunosuppressive treatment shown in RCT to
be superior to corticosteroids alone.599–602
Table 27 | Definitions of response to therapy in LN
Complete response: Return of SCr to previous baseline, plus a decline in
the uPCR to o500mg/g (o50mg/mmol).
Partial response: Stabilization (±25%), or improvement of SCr, but not to
normal, plus a X50% decrease in uPCR. If there was nephrotic-range
proteinuria (uPCRX3000mg/g [X300mg/mmol]), improvement requires
a X50% reduction in uPCR, and a uPCR o3000mg/g [o300mg/mmol].
Deterioration: There is no definition of deterioration in LN to define
treatment failure that has been tested prospectively as an indication to
change in initial therapy. A sustained 25% increase in SCr is widely used
but has not been validated.
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A lower-dose regimen using i.v. cyclophosphamide 500mg
every 2 weeks for 3 months (Regimen B, sometimes called the
‘‘Euro-Lupus regimen’’) had equivalent efficacy to Regimen A
in an RCT in Caucasians.603,604 However, few patients in the
Euro-Lupus trial had severe kidney disease, defined as rapidly
progressive kidney failure and typically with widespread
(450%) segmental glomerular necrosis or crescents. It
remains uncertain whether Regimen B has equivalent efficacy
to Regimen A in severe class III/IV LN, and in patients of
other ethnicities.
Oral cyclophosphamide 1.0–1.5mg/kg/d (maximum dose
150mg/d) for 2–4 months (Regimen C) has been used as an
alternative to i.v. cyclophosphamide.605,606 It has equivalent
efficacy to i.v. cyclophosphamide in prospective observational
studies,599,607–610 and has also been shown equivalent to
mycophenolate in Chinese patients,611,612 although this has
not yet been verified in other ethnicities. More adverse effects
have been reported with oral compared to i.v. cyclopho-
sphamide, but this is not a consistent finding.
Mycophenolate
MMF (maximum 3 g/d) for 6 months (Regimen D) has been
tested in an RCT in a Chinese population, and was equivalent
in achieving remission to Regimen C; patients with severe LN
were excluded from this study.612
An RCT known as the Aspreva Lupus Management Study
(ALMS)613 recruited 370 patients with class III, IV, and V LN,
and comparing MMF to Regimen A, showed that MMF
had an equivalent response rate to i.v. cyclophosphamide
at 6 months, and had a similar incidence of adverse events
including serious infections and deaths.613
Enteric-coated mycophenolate sodium may also be effec-
tive in LN, as suggested by a small trial in cyclophosphamide
resistant patients.614
Other regimens
There is more limited RCT evidence for the use of three other
regimens as initial treatment: corticosteroids combined with
(i) azathioprine; or (ii) cyclosporine; or (iii) the combination of
tacrolimus and MMF (sometimes called ‘‘multitarget’’ therapy).
Azathioprine
An RCT in Europeans compared initial therapy with
azathioprine combined with i.v. methylprednisone, followed
by oral prednisone, to i.v. cyclophosphamide with oral
prednisone.615 At 2 years, there was no difference in response
rate, and fewer adverse effects in those receiving azathioprine.
However, supplementary studies in these cohorts showed
a higher late relapse rate and higher risk of doubling of SCr
after azathioprine. Furthermore, there was more chronicity
on later biopsies after azathioprine.616
Cyclosporine
A small (n¼ 40), open-label RCT compared cyclosporine to
cyclophosphamide as initial therapy combined with corti-
costeroids for proliferative LN.617 Cyclosporine (4–5mg/
kg/d) was used for 9 months, and then tapered over the next
9 months. Cyclophosphamide was used in a different regimen
than in most published trials: eight i.v. pulses (10mg/kg)
were given in the first 9 months, and then four to five oral
pulses (10mg/kg) over the next 9 months. There were no
differences in responses or remissions at 9 or 18 months, or
relapse rate after 40 months of follow-up. Infections and
leukopenia did not differ between the groups.
Tacrolimus with Mycophenolate
In a small RCT from China in patients with combined
class IV and V LN, the combination of tacrolimus (4mg/d),
MMF (1 g/d), and oral corticosteroids (sometimes known
as ‘‘multitarget’’ therapy) was compared to pulse monthly
i.v. cyclophosphamide (0.75 g/m2 for 6 months) plus oral
corticosteroids. At 6 months, 90% of patients treated with
this multitarget therapy and 45% of patients treated with
cyclophosphamide achieved either complete or partial
remission (P¼ 0.002).618 This regimen has not yet been
evaluated in other ethnic groups.
Table 28 | Regimens for initial therapy in class III/class IV LN









dose 150mg/d) for 2–4 months
—
MMF — — — MMF up to 3 g/d
for 6 months
Benefit shown by
RCT in proliferative LN




Yes Untested Untested Untested
Comments Effective in whites,
blacks, Hispanics, Chinese
Effective in whites. Untested
in blacks, Hispanics, Chinese
Effective in whites, blacks, Chinese;
easy to administer and lower




LN, lupus nephritis; MMF, mycophenolate mofetil; RCT, randomized controlled trial.
All regimens include corticosteroids:
K Oral prednisone, initial dose up to 0.5–1mg/kg/d, tapering over 6–12 months according to clinical response.
K i.v. methylprednisolone is sometimes added initially for severe disease.
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The use of cyclophosphamide in the treatment of class
III/IV LN became routine after a prospective RCT demon-
strated that cyclophosphamide added to corticosteroids
reduced development of ESRD.599 Other studies showed that
adding cyclophosphamide to corticosteroids decreased LN
relapses, improved remission rate, and decreased develop-
ment of CKD.600–602 Retrospective analysis of repeat kidney
biopsies from selected patients who had participated in the
NIH trials showed that those receiving only corticosteroids
had a linear increase in the chronicity index over time
(median 44 months after treatment), whereas patients
receiving corticosteroids and cyclophosphamide (or other
immunosuppressive drugs) had no change in the chronicity
index,619 suggesting the immunosuppressive drugs prevented
progressive kidney scarring. A criticism of these studies is
the small number of patients, especially during long-term
follow-up.
There were no significant differences in outcome between
i.v. and oral cyclophosphamide in the original RCT that led
to the widespread use of Regimen A,599 but because bladder
toxicity (chemical cystitis) developed only in patients
receiving oral cyclophosphamide, i.v. cyclophosphamide
became the standard treatment599 (Online Suppl Tables
78–79). In this initial trial, patients were exposed to large
cumulative amounts of cyclophosphamide; oral cyclopho-
sphamide was used at doses up to 4mg/kg/d for a median of
4 years, far greater than now recommended, and i.v.
cyclophosphamide was continued for a median of 4 years.
Given the potential for developing hematologic malignancies
later in life, these large cumulative doses of cyclo-
phosphamide should be avoided. We suggest a lifetime
maximum of 36 g cyclophosphamide in patients with
systemic lupus.13,284 This is reflected in Regimens A–C.
There are other important considerations, when using
cyclophosphamide, to reduce its toxicity. The dose of
cyclophosphamide should be decreased by 20% or 30% in
patients with CrCl 25–50 and 10–25ml/min, respectively.620
The dose of i.v. cyclophosphamide should be adjusted to keep
the day 10–14 leucocyte count nadir X3000/ml. When using
oral cyclophosphamide, white blood cell counts should be
monitored weekly and cyclophosphamide dose should be
adjusted to keep leucocytes X3000/ml. Leukopenia requires
careful evaluation, since systemic lupus, as well as cyclopho-
sphamide, can cause suppression of bone marrow.
To minimize bladder toxicity with oral cyclophosphamide,
we suggest instructing patients to take cyclophosphamide in
the morning, and to drink extra fluid at each meal and at bed
time. The use of sodium-2-mercaptoethane (mesna) will also
minimize the risk of hemorrhagic cystitis when cyclo-
phosphamide is given as i.v. pulses.
To protect fertility, women should be offered prophylaxis
with leuprolide and men testosterone while cyclophos-
phamide is being given.621,622 Administration of leuprolide
must be timed carefully in relation to cyclophosphamide to
maximize benefit. Ovarian tissue cryopreservation is an
additional, but expensive, option. The efficacy of testosterone
in preserving fertility in males is poorly established, so sperm
banking should be offered.
Given the toxicity of cyclophosphamide, studies were
undertaken to determine if the dosing regimen could
be modified. An RCT has tested the efficacy of low-
dose, short-duration cyclophosphamide (Regimen B) in
Caucasians.603,604 This regimen resulted in a higher percen-
tage of remissions and a lower incidence of severe infections
than Regimen A, although the differences were not statis-
tically significant.604 Importantly, this low-dose cyclopho-
sphamide regimen had similar long-term outcomes (mean
follow-up of 10 years) to Regimen A603 (Online Suppl
Table 77). In this trial, the majority of patients were white,
and most patients did not have clinically severe disease.
Therefore, it is not certain whether this protocol will be
effective in patients of other ancestry, or in patients with
more severe class III/IV LN.
A cyclophosphamide-free regimen has been proposed
(Regimen D). MMF is used for the first 6 months of LN
treatment, instead of sequential cyclophosphamide followed
by MMF. The basis for this approach was three small studies
of MMF in Asia, and one larger study (140 patients) from the
USA.611,623–625 The Asian studies concluded MMF was
equivalent to cyclophosphamide, but the USA trial demon-
strated MMF was superior to i.v. cyclophosphamide,
although many patients did not achieve the target dose of
cyclophosphamide, and a significant percentage of patients
showed no response or withdrew from the study. An RCT
(ALMS)613 recruited 370 patients with class III, IV, and V LN,
giving oral corticosteroids and either daily oral MMF or
6-monthly i.v. pulses of cyclophosphamide (0.5–1 g/m2). The
ALMS trial showed that MMF was equivalent to i.v.
cyclophosphamide in inducing a response at 6 months.613
ALMS showed a similar incidence of adverse events, serious
infections, and deaths for MMF and cyclophosphamide
(Online Suppl Tables 71–73). Similar results were found in an
Egyptian cohort.626
A posthoc analysis of the ALMS trial indicated that black,
Hispanic, and mixed-race patients, (generally considered
to have more resistant LN627) had inferior outcomes
with cyclophosphamide compared to MMF. Further infor-
mation is required from RCTs before recommendations can
be made about the efficacy of MMF in patients of specific
ethnicity.
Because the kidney response rate for class III and IV LN
with any of the initial therapies so far discussed is only about
60% at 6–12 months, an RCT adding rituximab or placebo to
MMF plus corticosteroids for initial LN therapy was under-
taken to determine if remission rates could be improved.628
This RCT was based on several small, open-label, uncon-
trolled trials that suggested rituximab may be effective in
proliferative LN, either for refractory disease or as initial
therapy.629–635 At 12 months, however, there were no
differences between the rituximab and placebo groups in
terms of complete or partial remissions. Thus, rituximab
cannot be recommended as adjunctive initial therapy.
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Choice of Initial Therapy
The patients in the two largest studies of MMF vs.
cyclophosphamide generally had less severe LN, assessed by
level of proteinuria and kidney function,613,623 than the
patients in some of the RCTs of cyclophosphamide.601,636
Thus, in severe class III/IV LN, a cyclophosphamide-
containing protocol for initial therapy may be preferred.
However, a subset of patients in the ALMS trial did have
severe LN and responded to MMF, so more data are required.
In patients with less severe proliferative LN, an initial
regimen not containing cyclophosphamide should be
considered.
Additionally, the beneficial effect of cyclophosphamide
in preservation of kidney function was only apparent after
3–5 years of follow-up.599–601 This length of time, which was
needed to show a difference between initial therapies in long-
term kidney survival, must therefore be kept in mind when
evaluating new, non–cyclophosphamide-containing regimens
as initial therapy for class III/IV LN. For example, the Dutch
Working Party on systemic lupus found that azathioprine, an
antimetabolite like MMF, was equivalent to cyclophospha-
mide as initial therapy of class III and IV LN; however, in the
long term, repeat biopsies showed more chronic damage with
azathioprine, as well as a higher incidence of kidney relapse
and doubling of SCr (Online Suppl Tables 74–76).615,616 In
some regions where cost and drug availability are an issue, it
may be necessary to use azathioprine for initial treatment of
class III and IV LN.
In a long-term study of continuous MMF therapy
compared to initial cyclophosphamide followed by azathiopr-
ine, there were no significant differences in kidney function
between the groups after a median of 64 months.612 How-
ever, in the MMF group, more patients had relapses, pro-
longed proteinuria 41 g/d, and persistent SCr 42mg/dl
(4177 mmol/l). These combined clinical findings have been
associated, in other studies, with deterioration of kidney
function over time.
After the initial 6-month treatment period, the ALMS trial
was extended for 3 years to evaluate maintenance therapy
with either MMF or azathioprine.637 Although not designed
to compare the long-term efficacy of initial therapy on kidney
function, there was a (nonsignificant) trend toward fewer
treatment failures in those who received cyclophosphamide
as initial therapy as opposed to MMF. This result was
independent of whether maintenance therapy was azathio-
prine or MMF.
Thus, it cannot yet be stated that initial therapy with
MMF is equal to cyclophosphamide for proliferative LN with
respect to long-term kidney function.
12.4: Class III LN (focal LN) and class IV LN (diffuse LN)—
maintenance therapy
12.4.1: We recommend that, after initial therapy is
complete, patients with class III and IV LN
receive maintenance therapy with azathioprine
(1.5–2.5mg/kg/d) or MMF (1–2 g/d in divided
doses), and low-dose oral corticosteroids
(r10mg/d prednisone equivalent). (1B)
12.4.2: We suggest that CNIs with low-dose cortico-
steroids be used for maintenance therapy in
patients who are intolerant of MMF and
azathioprine. (2C)
12.4.3: We suggest that, after complete remission is
achieved, maintenance therapy be continued
for at least 1 year before consideration is given
to tapering the immunosuppression. (2D)
12.4.4: If complete remission has not been achieved
after 12 months of maintenance therapy,
consider performing a repeat kidney biopsy
before determining if a change in therapy is
indicated. (Not Graded)
12.4.5: While maintenance therapy is being tapered, if
kidney function deteriorates and/or protein-
uria worsens, we suggest that treatment be
increased to the previous level of immuno-
suppression that controlled the LN. (2D)
RATIONALE
K There is moderate-quality evidence from RCTs in patients
with class III/IV LN that prolonged maintenance therapy
after initial treatment is required.
K There is moderate-quality evidence that maintenance
therapy with azathioprine or MMF is superior to
maintenance with cyclophosphamide as judged by risk
of death, and risk of development of CKD.
K There is moderate-quality evidence that azathioprine and
cyclosporine A have comparable efficacy as maintenance
therapies for class III/IV LN.
K There is very low–quality evidence to guide the duration
of maintenance therapy after complete remission, but
most randomized studies of class III/IV LN have given
therapy for several years.
The need for maintenance therapy was suggested when
patients treated only with short-term (6 months) i.v.
cyclophosphamide therapy were shown to have an increased
frequency of kidney relapses.600
Choice of Maintenance Therapy
Presently, there are several options for maintenance therapy
after the initial treatment of proliferative LN. The data
currently available do not allow a definitive recommendation
as to the choice of agent for maintenance therapy, although
in a multiethnic cohort MMF was superior to azathioprine.
Patient-specific factors, such as desire for pregnancy or
occurrence of side-effects, should however be considered
when making this choice.
A cohort of mainly black and Hispanic patients with class
III/IV LN was treated with monthly i.v. cyclophosphamide
for up to seven cycles, followed by azathioprine or MMF, and
compared to patients treated with 6-monthly cyclophos-
phamide pulses followed by quarterly cyclophosphamide
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pulses for 1 year beyond remission.638 This study showed
that, over 72 months, the patients treated with maintenance
azathioprine or MMF were significantly less likely to reach
the composite end-point of death or CKD than the
cyclophosphamide maintenance group, and to experience
fewer adverse effects.
The MAINTAIN Nephritis Trial compared MMF with
AZA as maintenance therapy in a predominantly Caucasian
population after initial treatment with low-dose (Regimen B)
cyclophosphamide.639 They had not necessarily achieved
remission after initial therapy. The primary end-point was
time to kidney relapse. After at least 3 years of follow-up, this
trial found MMF and azathioprine to be equivalent.
The ALMS trial extension phase637 compared MMF and
AZA as maintenance therapies after the 6-month initial
treatment period (Regimen D). Patients entered this exten-
sion phase only if they achieved a complete or partial
remission after initial therapy. Over 3 years, the composite
treatment failure end-point (death, ESRD, kidney flare,
sustained doubling of SCr, or requirement for rescue therapy)
was reached in 16% of MMF-treated patients compared
to 32% of azathioprine-treated patients (P¼ 0.003). The
superiority of MMF over azathioprine was not dependent on
initial therapy or race of the patient.
A pilot RCT in 69 patients with class III/IV LN suggested
that 2 years of cyclosporine may be as effective as 2 years of
azathioprine for maintenance, after initial treatment with
prednisone and oral cyclophosphamide, in terms of relapse
prevention and reduction of proteinuria.606 Another RCT
showed cyclosporine was as effective as azathioprine in terms
of tapering maintenance corticosteroids in severe systemic
lupus, but only 29% of the patients had LN.640
Duration of Therapy
Few patients reach complete remission by 6 months, and
kidney biopsies after 6 months of initial therapy have shown
that, while active inflammation tends to improve, complete
resolution of pathologic changes is unusual.614,625,641,642
Consistent with this finding, clinical improvement in class
III/IV LN continues well beyond 6 months and into the
maintenance phase of therapy.603,605,607,610,615,643 Decisions
to alter therapy should not be based on urine sediment alone.
A repeat kidney biopsy may be considered if kidney function
is deteriorating.
There is no evidence to help determine the duration of
maintenance therapy. The average duration of immunosup-
pression was 3.5 years in seven RCTs.599,600,603,604,609,612,615,638
We suggest that immunosuppressive therapy should usually
be slowly tapered after patients have been in complete
remission for a year. If a patient has a history of kidney
relapses it may be prudent to extend maintenance therapy.
Immunosuppression should be continued for patients
who achieve only a partial remission. However, the strategy of
trying to convert a partial remission to a complete remission
by increasing corticosteroids or using alternative immuno-
suppressive agents is not supported by evidence.
There are few data on repeat biopsies after therapy. Biopsies
taken two or more years after initial therapy often continue to
show activity, especially when there is still significant
proteinuria or an abnormal SCr.644 Of more concern, one
study found that, in patients with initial class III and IV LN,
only 40% had reverted to class II LN on repeat biopsy after
2 years of immunosuppressive therapy.616 The SCr and extent
of proteinuria at the time of the second biopsy did not
differentiate between the group that reverted to class II and the
group that remained with class III or IV LN.
Predictors of Response to Treatment of Class III/IV LN
Reported response rates are affected by variability in the
definition of remission and variability of initial treatment
regimens. Although complete remission should be the goal
for LN, attaining at least a partial remission significantly
improves kidney prognosis and patient mortality compared
to no remission.645
The 6- to 12-month response rates (both complete and
partial) from several trials involving black, white, Hispanic,
Mexican, and mixed-race patients are between 20% and
85%.604,605,613,615,623,638 Complete remission rates at
6–12 months were between 8% and 30% in these studies.
In contrast, Chinese patients in clinical trials had a
consistently better response rate of about 90% and a
complete remission rate of 60–80%.607–609,611
Multivariate analyses of retrospective studies suggest that
the most important predictors for not achieving remission are
SCr at the start of treatment (RR 0.21 per 1mg/dl [88mmol/l]),
the magnitude of increase in SCr during relapse, a delay in
starting therapy for more than 3 months after a clinical
diagnosis of LN, and severity of proteinuria (HR 0.86 per 1 g/d
proteinuria [uPCR 1000mg/g or 100mg/mmol]).627,643
In one prospective study there were no clinical variables
predictive of achieving remission on multivariate analysis,609
while another prospective study showed initial SCr was a
predictor of complete remission (RR¼ 0.96 per mmol/l
[0.0113mg/dl] increase in SCr).608
Multivariate analysis from a prospective study showed
that failure to achieve complete remission was a major risk
factor for kidney relapse,607 while other studies found that
no variables were independently predictive of relapse.616
A survey of several retrospective studies shows that the one
common predictor for risk of CKD, ESRD, or death is SCr
at presentation.627,646–648 In children with LN, failure to
respond to therapy and kidney relapse were risk factors for
ESRD, HR 5.5 and 11.8 respectively.649
Monitoring Therapy of Class III/IV LN
The progress of LN therapy is monitored with serial
measurements of proteinuria and SCr. There are not yet
any more sensitive biomarkers of kidney response in lupus of
proven clinical value.650 In LN, as in other proteinuric GN,
resolution of proteinuria is the strongest predictor of kidney
survival;477,651,652 thus, effective treatment is expected to
decrease proteinuria over time.
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Effective therapy is also expected to result in reduction of
an elevated SCr. A caveat is that there may be may be an
acceptable increment in SCr in association with concomitant
RAS blockade. Urine sediment should be monitored serially
during LN therapy, specifically looking for resolution of
cellular casts over time. However, hematuria may persist for
months even if therapy is otherwise successful in improving
proteinuria and kidney dysfunction. It is desirable to see
serologic markers of lupus activity, such as complement and
double-stranded DNA antibody levels, normalize with
treatment. However, C3 and C4, and anti–double-stranded
DNA antibodies have low sensitivity (49–79%) and specificity
(51–74%) in relationship to LN activity.653–659
RESEARCH RECOMMENDATIONS
K RCTs are needed to compare the efficacy of MMF and
cyclophosphamide as initial therapy in non-Caucasian
patients.
K RCTs are needed to examine steroid-free and steroid-
limited regimens.
K An RCT is needed to determine the duration of
maintenance therapy in proliferative LN after complete
remission.
K Studies are needed to determine if repeat biopsy of
patients who achieve only partial remission can guide
therapy to achieve complete remission.
K Biomarkers need to be identified that reflect response to
therapy and kidney pathology. These would then need to
be tested to determine whether they could be used to
guide treatment withdrawal, re-treatment, and change in
treatment.
12.5: Class V LN (membranous LN)
12.5.1: We recommend that patients with class V LN,
normal kidney function, and non–nephrotic-
range proteinuria be treated with antiprotei-
nuric and antihypertensive medications, and
only receive corticosteroids and immunosup-
pressives as dictated by the extrarenal man-
ifestations of systemic lupus. (2D)
12.5.2: We suggest that patients with pure class V LN
and persistent nephrotic proteinuria be trea-
ted with corticosteroids plus an additional
immunosuppressive agent: cyclophosphamide
(2C), or CNI (2C), or MMF (2D), or azathio-
prine (2D).
BACKGROUND
In class V LN, light microscopy typically shows thickened
glomerular basement membranes; immunofluorescence and
electron microscopy show only subepithelial immune com-
plexes. If class V LN is accompanied by endocapillary
hypercellularity and/or subendothelial immune deposits, this
adds class III or IV to the histologic diagnosis. In class V LN,
the main clinical finding is proteinuria, often nephrotic-
range, with or without hematuria; kidney function is usually
normal. If class III or IV LN is also present, urine sediment
may be more active, and kidney impairment is more likely.
RATIONALE
K Pure class V LN, although regarded as indolent compared to
class III and IV LN, is still associated with the development
of CKD and ESRD, especially if there is heavy proteinuria.
K Nephrotic-range proteinuria in class V LN generally does
not spontaneously remit.
K There has only been one small RCT in class V LN, which
compared corticosteroids plus immunosuppression to
corticosteroids alone.
K There have been a few small, retrospective trials of MMF
and azathioprine in class V LN.
K There have been no studies of the effect of treatment of
class V LN on long-term kidney outcomes.
K The prognosis for patients with mixed membranous and
proliferative lesions [i.e., class V plus class III or IV LN] is
less favorable than pure class V LN, and similar to that of
patients with class III or IV LN. Patients with mixed
membranous and proliferative lesions should be treated
similarly to those with class III and IV LN.
There are no convincing data to treat class V LN and
subnephrotic proteinuria with immunosuppression; however,
given the adverse effects of proteinuria on the kidney, it is
reasonable to treat these patients with antiproteinuric and
antihypertensive medications (see Chapter 2). These thera-
pies may reduce proteinuria by as much as 30–50% in class V
LN.486,652,660 They should also be used as an adjunct
to immunosuppression for patients with nephrotic-range
proteinuria.
The justifications to treat class V LN and nephrotic
proteinuria with immunosuppression are as follows. De-
creased GFR occurs in about 20% of cases of class V LN, and
ESRD in about 8–12% after 7–12 years,661–664 with one study
reporting death or ESRD in 28% of patients at 10 years.665
Spontaneous remission of heavy proteinuria occurs in only a
minority of class V LN.666,667 The adverse effects of sustained,
heavy proteinuria include hyperlipidemia and atherosclerosis,
contributing to cardiovascular morbidity and morta-
lity,652,668 and hypercoagulability with arterial and venous
thromboses.588,652 Thrombotic events occur in 13–23% of
class V LN, and have been associated with antiphospholipid
antibodies, and/or the nephrotic syndrome.661,664,669
There is only one small RCT (n¼ 15 in each treatment
arm) examining the treatment of class V LN.670 This study
compared the addition of cyclophosphamide or cyclosporine
to prednisone in a USA cohort that included blacks,
Hispanics, and whites. Both cyclophosphamide and cyclo-
sporine significantly increased response (complete remission
40–50% vs. 14% at 12 months). However, relapse after
stopping therapy was much more likely in those treated with
cyclosporine (40% within 1 year) compared to cyclophos-
phamide (no relapse in 48 months). In the same study, the
only independent predictor of failure to achieve remission
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(by multivariate analysis) was initial proteinuria over 5 g/d.
Failure to achieve sustained remission was a risk factor for
decline in kidney function (Online Suppl Tables 82–84).
There have been small uncontrolled retrospective, or
open-label, studies of MMF and azathioprine with or without
corticosteroids in class V LN.663,669,671,672 In general, these
studies have shown complete remission rates of 40–60% at
6–12 months. A small open-label trial of tacrolimus in class V
LN showed a complete remission rate of 39% at 6 months.673
Before these regimens can be recommended, they will need to
be tested in RCTs.
Patients with mixed class V and class III or IV LN may
have a less favorable prognosis, and should be treated as for
the proliferative component.664
RESEARCH RECOMMENDATION
K An RCT is needed to compare MMF to cyclophos-
phamide or a CNI, for induction of remission of pure
class V LN.
12.6: General treatment of LN
12.6.1: We suggest that all patients with LN of any
class are treated with hydroxychloroquine
(maximum daily dose of 6–6.5mg/kg ideal
body weight), unless they have a specific
contraindication to this drug. (2C)
RATIONALE
K There is low-quality evidence that hydroxychloroquine
may protect against the onset of LN, against relapses of
LN, ESRD, vascular thrombosis, and that it has a
favorable impact on lipid profiles.674
In a prospective study, hydroxychloroquine was main-
tained or withdrawn in a cohort of patients who had been
receiving it before the diagnosis of LN.675 Those who had
been on hydroxychloroquine before developing LN had a
lower frequency of ESRD, cardiovascular events, and
thrombotic events than patients who had never received
hydroxychloroquine; HR for ESRD 0.29 (95% CI
0.026–1.009).676 A large (n¼ 1930), retrospective study found
that treatment with hydroxychloroquine protected against
vascular thrombosis (OR 0.62; Po0.0005).677 Finally, in a
prospective observational cohort, hydroxychloroquine was
shown to retard kidney damage in LN; the cumulative
probability of a 50% reduction in GFR or ESRD after 10 years
was 38% for patients on hydroxychloroquine and 70% for
those who were not (Po0.0001).678 Patients on hydroxy-
chloroquine should have yearly eye examinations for retinal
toxicity, especially after 5 years of continuous use.
12.7: Class VI LN (advanced sclerosis LN)
12.7.1: We recommend that patients with class VI LN
be treated with corticosteroids and immuno-
suppressives only as dictated by the extrarenal
manifestations of systemic lupus. (2D)
BACKGROUND
In class VI LN, at least 90% of the glomeruli are sclerotic,
usually globally, along with interstitial fibrosis and tubular
atrophy, with no signs of immunologic activity; the biopsy
specimen should be sufficient to be representative of the
whole kidney. The dominant clinical picture in class VI LN is
severe kidney impairment, usually accompanied by protei-
nuria and sometimes hematuria.
RATIONALE
K Class VI LN reflects chronic injury, and the consequences
of the loss of functional kidney mass, without active
immune-mediated injury. Therefore, immunosuppres-
sion is not indicated.
K Despite the absence of active LN, patients may still have
extrarenal manifestations of systemic lupus requiring
immunosuppression.
K As with CKD from any etiology, antiproteinuric and anti-
hypertensive therapies are indicated to preserve residual
kidney function and delay ESRD as long as possible.
12.8: Relapse of LN
12.8.1: We suggest that a relapse of LN after complete
or partial remission be treated with the initial
therapy followed by the maintenance therapy
that was effective in inducing the original
remission. (2B)
12.8.1.1: If resuming the original therapy would
put the patient at risk for excessive
lifetime cyclophosphamide exposure,
then we suggest a non–cyclophos-
phamide-based initial regimen be used
(Regimen D, Table 28). (2B)
12.8.2: Consider a repeat kidney biopsy during
relapse if there is suspicion that the histologic
class of LN has changed, or there is uncer-
tainty whether a rising SCr and/or worsening
proteinuria represents disease activity or
chronicity. (Not Graded)
RATIONALE
K LN is a relapsing condition.
K Relapses are associated with development of CKD.
K The pathologic findings in LN may change with a relapse,
and such changes cannot, with certainty, be predicted
clinically.
In subjects with LN who had participated in RCTs, 40% of
complete responders experienced a kidney relapse within a
median of 41 months after remission, and 63% of partial
responders had a kidney flare within a median of 11.5
months after response.679 The strongest risk factor for relapse
is failure to achieve complete remission (HR 6.2).607
Relapses are important to recognize and treat, because
the kidneys sustain some chronic damage with each relapse
that may culminate in CKD, or eventually ESRD. This is
228 Kidney International Supplements (2012) 2, 221–232
chapte r 12
supported by repeat biopsy studies that showed an increase
in the chronicity index at the second biopsy, even after
successful treatment.614,616,618,625,641,644,680
LN may spontaneously transform from one class to
another. The most common transformation is from class III
to IV.644 Also, a recent retrospective study found clinically
relevant class transformation to be more frequent from a
nonproliferative to a proliferative class, rather than prolif-
erative to nonproliferative transformation.681 Clues to a
change in LN class are the development of nephrotic-range
proteinuria and changes in the activity of urine sediment, but
definitive diagnosis requires a biopsy.
Kidney relapse is diagnosed by clinical criteria based on
changes in urine sediment, rate of protein excretion, and SCr
change from baseline values in an individual patient. There is
no consensus on the definition of a kidney relapse; criteria
used in several published studies are shown in Table 29.682–686
A fall in levels of serum complement components and a rise
in anti–double-stranded DNA antibody titers also support a
diagnosis of relapse but will not necessarily be present.
RESEARCH RECOMMENDATION
K A study of repeat kidney biopsies at the time of kidney
relapse is needed to determine whether it is beneficial
to tailor therapy based on biopsy findings.
12.9: Treatment of resistant disease
12.9.1: In patients with worsening SCr and/or protei-
nuria after completing one of the initial
treatment regimens, consider performing a
repeat kidney biopsy to distinguish active LN
from scarring. (Not Graded)
12.9.2: Treat patients with worsening SCr and/or
proteinuria who continue to have active LN on
biopsy with one of the alternative initial treat-
ment regimens (see Section 12.3). (Not Graded)
12.9.3: We suggest that nonresponders who have
failed more than one of the recommended
initial regimens (see Section 12.3) may be
considered for treatment with rituximab, i.v.
immunoglobulin, or CNIs. (2D)
RATIONALE
K Most patients are expected to show some evidence of
response to treatment after a year of therapy, although
complete remission may occur beyond a year.
K There are no prospective data on patients who fail to
achieve at least partial response; it is reasonable, however,
to repeat biopsy and determine if there has been a change
in kidney pathology that could account for treatment
failure.
K There are no prospective data on patients who fail initial
therapy; however, it is reasonable to try a second course
of initial therapy using an alternative regimen, as dictated
by repeat biopsy.
K There have been small studies of ‘‘rescue’’ therapies for
patients who have been refractory despite multiple
treatment attempts.
In both prospective and retrospective LN cohorts, despite
treatment with different protocols and follow-up under
different definitions of remission, the majority of patients
who remitted did so within 1 year of therapy.604,605,615,618,645
Studies generally show that 50% of patients had a remission
(complete or partial) by 12 months, with another 5–25%
remitting by 24 months. Among complete remissions, about
half were achieved by 12 months, and the other half by
20–24 months.
Table 29 | Criteria for the diagnosis and classification of relapses of LN
Mild kidney relapse Moderate kidney relapse Severe kidney relapse
Increase in glomerular hematuria
from o5 to 415 RBC/hpf, with
Z2 acanthocytes/hpf
If baseline creatinine is: If baseline creatinine is:
and/or
o2.0mg/dl [o177mmol/l], an increase of
0.20–1.0mg/dl [17.7–88.4mmol/l]
o2mg/dl [o177mmol/l], an increase of
41.0mg/dl [488.4mmol/l]
recurrence of Z1 RBC cast, WBC
cast (no infection), or both
X2.0mg/dl [X177mmol/l], an increase of




If baseline uPCR is:
o500mg/g [o50mg/mmol], an increase to
X1000mg/g [X100mg/mmol]
an absolute increase of uPCR 45000mg/g
[4500mg/mmol]
500–1000mg/g [50–100mg/mmol], an increase to
X2000mg/g [X200mg/mmol], but less than absolute
increase of o5000mg/g [o500mg/mmol]
41000mg/g [4100mg/mmol], an increase of X2-fold
with absolute uPCR o5000mg/g [o500mg/mmol]
hpf, high-power field; LN, lupus nephritis; RBC, red blood cell; uPCR, urine protein:creatinine ratio; WBC, white blood cell.
Adapted from Lahita RG, Tsokos GT, Buyon JP, Koike T (eds). Systemic Lupus Erythematosus, 5th edn. Rovin BH, Stillman IE. Chapter 42: Kidney. Elsevier: Waltham, MA, 2011,
pp 769–814 with permission from Elsevier.687
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There is no consensus definition of refractory LN. A
patient may be considered refractory if conventional cyclo-
phosphamide regimens have been tried without success, and
non-cyclophosphamide regimens have not worked. If repeat
kidney biopsy confirms active LN is the cause of continuing
clinical abnormalities, there is no definitive information to
guide therapy. The following ‘‘salvage’’ treatments have only
been evaluated in small observational studies.
The evidence that refractory LN can be treated with
rituximab comes only from small, open-label studies.623,688
Many of these patients had failed multiple attempts at
treatment with the conventional therapies described pre-
viously. Rituximab may be considered as a ‘‘rescue therapy’’
when usual therapeutic options have been exhausted. This
use of rituximab is in contrast to its lack of utility as add-on
therapy to an initial standard regimen (Regimen D) for
proliferative LN.642
The evidence for using i.v. immunoglobulin in refractory
cases is of very low quality. It has been used in a handful of
patients with proliferative LN, and in some has shown
comparable efficacy to cyclophosphamide (reviewed by
Rauova et al.689 Some formulations of i.v. immunoglobulin
(sucrose-containing) have shown nephrotoxicity, and are
therefore best avoided in patients with pre-existing kidney
impairment.
There is only evidence from small prospective, open-label
trials for using low-dose cyclosporine (2.5mg/kg/d) to treat
refractory LN.690,691 Although kidney function did not
improve, most patients had a reduction in proteinuria,
resolution of hematuria, and needed lower doses of
corticosteroids. Similarly, a prospective trial used tacrolimus
(3mg/d) in patients with LN in whom corticosteroids could
not be reduced, and demonstrated improvement in protei-
nuria and C3 levels.692
RESEARCH RECOMMENDATIONS
K A globally accepted definition of nonresponse needs to be
developed.
K The salvage therapies discussed in the text must be
subject to RCTs to determine effect on remission and
kidney outcomes.
12.10: Systemic lupus and thrombotic microangiopathy
12.10.1: We suggest that the antiphospholipid anti-
body syndrome (APS) involving the kidney in
systemic lupus patients, with or without LN,
be treated by anticoagulation (target interna-
tional normalized ratio [INR] 2–3). (2D)
12.10.2: We suggest that patients with systemic lupus
and thrombotic thrombocytopenic purpura
(TTP) receive plasma exchange as for patients
with TTP without systemic lupus. (2D)
BACKGROUND
Lupus-associated thrombotic microangiopathies (TMA) may
occur alone or in combination with immune-complex LN.
TMA in systemic lupus may occur in association with
accelerated hypertension, systemic sclerosis, TTP, or in lupus
anticoagulant/APS.
While TMA associated with APS, TTP, and accelerated
hypertension is often characterized by AKI, APS can also
cause slowly progressive kidney impairment with few specific
clinical manifestations. In retrospective studies, kidney APS
occurred in about 30% of systemic lupus patients.693,694
Lupus anticoagulant was present in 30–52% of those with
kidney APS, while 72–95% of patients had anticardiolipin
antibodies, but 15% had neither of these serologic
markers.693,695 Routine testing does not identify all anti-
phospholipid antibodies; therefore, those with TMA who are
antiphospholipid antibody–negative are treated in the same
way as antibody-positive patients. A high index of suspicion
is needed along with a kidney biopsy to confirm the
diagnosis.
RATIONALE
K APS occurs frequently in systemic lupus, and there is
moderate-quality evidence that failure to treat it may lead
to CKD or ESRD, despite adequate control of LN or other
systemic lupus manifestations with immunosuppression.
K Although there are no specific studies of anticoagulation
for APS with systemic lupus, there have been two RCTs
of the intensity of warfarin therapy in APS.696,697 They
provided moderate-quality evidence of no difference in
thrombotic events if the INR was 2–3 or 3–4, but that
bleeding complications were higher when INR was
maintained greater than 3.
K TTP in lupus is associated with a high mortality.698 There
are no RCTs to guide treatment of TTP in the setting of
systemic lupus, but it seems appropriate to use regimens
beneficial in TTP without lupus.
RESEARCH RECOMMENDATIONS
K A clinical trial is needed to determine the effect of
treating APS on long-term kidney function.
K A clinical trial is needed to determine the efficacy of
plasma exchange in TTP, in the setting of systemic lupus.
12.11: Systemic lupus and pregnancy
12.11.1: We suggest that women be counseled to
delay pregnancy until a complete remission
of LN has been achieved. (2D)
12.11.2: We recommend that cyclophosphamide,
MMF, ACE-I, and ARBs not be used during
pregnancy. (1A)
12.11.3: We suggest that hydroxychloroquine be
continued during pregnancy. (2B)
12.11.4: We recommend that LN patients who
become pregnant while being treated with
MMF be switched to azathioprine. (1B)
12.11.5: We recommend that, if LN patients relapse
during pregnancy, they receive treatment
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with corticosteroids and, depending on the
severity of the relapse, azathioprine. (1B)
12.11.6: If pregnant patients are receiving cortico-
steroids or azathioprine, we suggest that
these drugs not be tapered during pregnancy
or for at least 3 months after delivery. (2D)
12.11.7: We suggest administration of low-dose
aspirin during pregnancy to decrease the
risk of fetal loss. (2C)
RATIONALE
K Data suggest that active LN or LN in partial remission is
associated with an increase in fetal loss and an increased
rate of kidney relapse during pregnancy.
K Cyclophosphamide, MMF, ACE-I, and ARBs are terato-
genic.
K Hydroxychloroquine, azathioprine, and corticosteroids
have been used safely during pregnancy in patients with
systemic lupus; low-dose aspirin may decrease fetal loss in
systemic lupus.
The risk of fetal loss in patients with LN has been
examined in several retrospective series. In a nested case-
control study of 78 pregnancies, the incidence of fetal loss
was not different in patients with a history of LN compared
to systemic lupus patients with no history of LN.699 In
patients with LN in remission, fetal loss of 8–13% has been
documented.700–702 However, in patients with active LN, fetal
loss was significantly higher at 35%.702 In addition to the
clinical activity of LN, hypocomplementemia appears to be a
risk factor for fetal loss, whereas the use of low-dose aspirin
may be protective. In a retrospective study of 113 pregnancies
in patients with systemic lupus and LN, hypocomplemente-
mia conferred a RR of 19 for fetal loss, and aspirin conferred
a RR of 0.11.701 All the patients in this investigation were
Caucasian, so the results may not be applicable to other
ethnicities.
Hydroxychloroquine should be continued in pregnancy
because its withdrawal may lead to flares of lupus, including
LN.703
There may be additional risk to the kidneys of patients
with LN who become pregnant. One study noted that kidney
relapses and progressive kidney dysfunction were not
different between pregnant and nonpregnant patients with
LN.699 In other studies, kidney relapses were more common
in pregnancies occurring when only partial remission of LN
had been achieved, or in patients who had more than 1 g/d
proteinuria or kidney impairment.700–702 Kidney relapse
rates of 10–69% have been reported during or following
pregnancy.699–702
12.12: LN in children
12.12.1: We suggest that children with LN receive the
same therapies as adults with LN, with
dosing based on patient size and GFR. (2D)
RATIONALE
K LN in children shows the same range of clinical and
pathological phenotypes as is seen in adults.
K There are no RCTs of LN therapy in children.
Therefore, we suggest that children with LN be treated with
the regimens recommended earlier in this chapter. The
research recommendations made under 12.1–12.10 also apply
to children.
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